TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from OS Therapies Incorporated ( (OSTX) ).
On September 30, 2025, OS Therapies Incorporated filed a prospectus supplement with the SEC, which is part of their registration statement. This filing allows for the resale of up to 4,373,043 shares of the company’s common stock by selling stockholders, and includes a legal opinion on the legality of these shares.
The most recent analyst rating on (OSTX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.
Spark’s Take on OSTX Stock
According to Spark, TipRanks’ AI Analyst, OSTX is a Underperform.
OS Therapies Incorporated faces significant financial difficulties, marked by increasing net losses, negative cash flows, and reliance on external financing. The technical analysis indicates bearish momentum with the stock trading below its moving averages. Valuation is challenging with no earnings to support a P/E ratio or dividend yield. These factors contribute to a low overall stock score, reflecting the company’s financial instability and negative market sentiment.
To see Spark’s full report on OSTX stock, click here.
More about OS Therapies Incorporated
Average Trading Volume: 618,612
Technical Sentiment Signal: Strong Sell
Current Market Cap: $63.61M
Learn more about OSTX stock on TipRanks’ Stock Analysis page.